Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Inventory (2016 - 2025)

Vanda Pharmaceuticals' Inventory history spans 14 years, with the latest figure at $11.0 million for Q4 2025.

  • On a quarterly basis, Inventory rose 538.47% to $11.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.0 million, a 538.47% increase, with the full-year FY2025 number at $11.0 million, up 538.47% from a year prior.
  • Inventory hit $11.0 million in Q4 2025 for Vanda Pharmaceuticals, up from $10.0 million in the prior quarter.
  • Over the last five years, Inventory for VNDA hit a ceiling of $11.5 million in Q4 2022 and a floor of $902000.0 in Q3 2021.
  • Historically, Inventory has averaged $4.8 million across 5 years, with a median of $1.8 million in 2024.
  • Biggest five-year swings in Inventory: skyrocketed 1020.98% in 2022 and later plummeted 85.57% in 2024.
  • Tracing VNDA's Inventory over 5 years: stood at $1.0 million in 2021, then skyrocketed by 1020.98% to $11.5 million in 2022, then fell by 11.18% to $10.2 million in 2023, then plummeted by 83.09% to $1.7 million in 2024, then skyrocketed by 538.47% to $11.0 million in 2025.
  • Business Quant data shows Inventory for VNDA at $11.0 million in Q4 2025, $10.0 million in Q3 2025, and $2.2 million in Q2 2025.